Autoimmune pulmonary alveolar proteinosis with primary lung cancer in a patient of very advanced years

Iwakami, Shin‐ichiro; Fujii, Mitsuhiro; Tsutsumi, Takanobu; Sekimoto, Yasuhito; Jo, Hyun Hee; Hara, Munechika; Iwakami, Naoko; Takahashi, Kazuhisa

doi:10.1111/ggi.12445

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion2

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several reports of other anticancer agents employed to treat primary lung cancer with PAP, such as EGFR-tyrosine kinase inhibitor, cisplatin, pemetrexed, and vinorelbine [ [7] , [8] , [9] ]. Among those, only one detailed a patient with kidney cancer with PAP that used ICI as treatment [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Primary lung cancer with pulmonary alveolar proteinosis treated with immune checkpoint inhibitor: A case report

Horie,

Nakashima,

Amano

et al. 2024

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Primary lung cancer with pulmonary alveolar proteinosis treated with immune checkpoint inhibitor: A case report

Horie,

Nakashima,

Amano

et al. 2024

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

“…We collected 10 previous case reports of PAP with lung cancer combined from the PubMed and the Japan Medical Abstracts Society databases using the keywords "Pulmonary alveolar proteinosis lung cancer" (Table) (4,5,(10)(11)(12)(13)(14)(15)(16). The search was limited to English and Japanese languages only.…”

Section: Discussionmentioning

confidence: 99%

Autoimmune Pulmonary Alveolar Proteinosis with Suspected Exacerbation after Osimertinib Administration for Lung Cancer

et al. 2023

View full text Add to dashboard Cite

A 46-year-old woman with lung cancer who received chemotherapy was admitted to our hospital for lower-lobe bilateral ground-glass opacity (GGO). GGO developed after the lung cancer diagnosis, deteriorated after the initiation of osimertinib, and incompletely decreased after interrupting osimertinib; therefore, flexible bronchoscopy was performed. Transbronchial lung biopsy histology and anti-granulocyte/macrophage colony-stimulating factor autoantibody positivity revealed autoimmune pulmonary alveolar proteinosis (aPAP) that did not require treatment. This rare case of aPAP comorbid with lung cancer suggested that using PAP findings to differentiate from drug-induced lung injury or lymphangitis is difficult and that osimertinib was suspected to exacerbate aPAP.

show abstract

“…The lung cancer may occur prior to[ 5 ] coincidentally with[ 5 ] or after many years of diagnosis of PAP. [ 6 ]…”

mentioning

confidence: 99%

A rare case of secondary pulmonary alveolar proteinosis with adenocarcinoma of lung with retroviral disease

et al. 2020

View full text Add to dashboard Cite

Autoimmune pulmonary alveolar proteinosis with primary lung cancer in a patient of very advanced years

Cited by 5 publications

References 8 publications

Primary lung cancer with pulmonary alveolar proteinosis treated with immune checkpoint inhibitor: A case report

Primary lung cancer with pulmonary alveolar proteinosis treated with immune checkpoint inhibitor: A case report

Autoimmune Pulmonary Alveolar Proteinosis with Suspected Exacerbation after Osimertinib Administration for Lung Cancer

A rare case of secondary pulmonary alveolar proteinosis with adenocarcinoma of lung with retroviral disease

Contact Info

Product

Resources

About